What happened with PBH today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Prestige Consumer Healthcare owns consumer health brands including Clear Eyes, Compound W, Dramamine and Monistat. Consumers buy its products through stores and online, while retailers and distributors pay the company for the products they purchase. Most revenue comes from its North American over-the-counter healthcare business, with a smaller business in Australia and other international markets. It develops its brands through advertising, new formulations and product extensions, and adds brands through acquisitions.
Walmart and Amazon together supply a substantial share of revenue. Customers generally buy through individual orders rather than long-term contracts, so sales depend on continued purchasing and shelf space or online placement.
Prestige relies primarily on outside manufacturers, although it also operates its own factories. One outside manufacturer makes products that account for a substantial share of sales. Product availability depends on these suppliers and compliance with manufacturing rules, including U.S. Food and Drug Administration standards. Stricter requirements for sterile eye-care products have contributed to manufacturing constraints and shortages. Regulatory noncompliance can stop production or sales.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Prestige’s results hinge on demand for its OTC brands and reliable manufacturing supply; Bayer, Reckitt Benckiser and Opella are important competitors to watch beyond this list.
Perrigo competes for the same retail shoppers as Prestige by making OTC remedies sold under retailers’ own brands at lower prices than national brands. Watch its North American store-brand sales for signs of shoppers choosing cheaper alternatives to branded remedies.
Haleon competes with Prestige for consumers buying pain relief, respiratory, digestive, oral-health and skin-health products. Its digestive-health sales are worth watching alongside Prestige’s gastrointestinal revenue for demand and competition in that category.
Kenvue competes with Prestige for retail buyers of pain relief and skin treatments through Tylenol and its therapeutic skin-care brands. News about those products’ retail availability and new launches is more relevant to Prestige’s analgesic and dermatological sales than Kenvue’s overall revenue.
Bausch + Lomb sells OTC eye drops to consumers that compete directly with Prestige’s Clear Eyes and TheraTears. Watch its consumer eye-drop sales rather than its broader eye-health business: Prestige’s fiscal 2026 North American OTC revenue decline was primarily driven by difficulty supplying Clear Eyes demand.
Alcon’s ocular-health products compete for consumers buying Prestige’s eye-care brands, but surgical products and contact lenses account for much of Alcon’s business. Focus on its ocular-health sales within Vision Care, rather than total sales, when assessing competition for Clear Eyes and TheraTears.
Procter & Gamble competes with Prestige for consumers buying healthcare products through retail stores and online, though these products make up a smaller part of P&G’s diversified daily-use business. Watch its OTC-remedy and oral-care activity rather than treating overall P&G sales as a guide to Prestige’s demand.
Bausch + Lomb Corporation earningsBLCO
Bausch + Lomb’s report will show how active the consumer eye-drop market is, where its products compete with Prestige Consumer Healthcare’s Clear Eyes and TheraTears for shoppers.
Watch Bausch + Lomb’s consumer eye-drop sales, not its surgical or broader eye-health business. Stronger sales would mean more active competition for Prestige’s eye-care brands; weaker sales could mean less pressure, but would not show whether Prestige has resolved Clear Eyes supply constraints.
Kenvue Inc. earningsKVUE
Kenvue’s report will show how shoppers are buying pain-relief and skin-treatment products, categories where it competes with Prestige Consumer Healthcare for retail shelf space and customers.
Focus on sales, launches, and retail availability for Kenvue’s pain-relief and therapeutic skin-care brands, not its total revenue. Stronger sales and availability would mean more active competition for Prestige’s analgesic and dermatological brands; weakness would suggest less pressure from this rival, not proof that Prestige’s own demand has improved.
PERRIGO COMPANY PLC earningsPRGO
Perrigo’s report will show whether shoppers are buying more retailers’ lower-priced over-the-counter remedies, which compete with Prestige Consumer Healthcare’s branded products.
Watch changes in Perrigo’s North American store-brand business and whether retailers and shoppers favor its lower-priced OTC remedies. Stronger sales would suggest greater substitution pressure on Prestige’s brands; weaker sales would suggest less pressure, but would not prove Prestige regained shelf space or sales.
Prestige Consumer Healthcare Inc. earningsThis company
Prestige Consumer Healthcare’s report will show whether it can turn demand for Clear Eyes and other eye-and-ear products into sales and support profit after advertising and marketing costs.
Read eye-and-ear sales alongside contribution margin, which is gross profit after advertising and marketing costs, as a share of revenue. Rising sales with a steadier margin would suggest supply is better meeting demand and brand sales are supporting marketing; weak sales or a further margin decline would show that supply limits or costs still weigh on the business.
